(MedPage Today) — Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen (PSMA) PET/CT, a retrospective…
(MedPage Today) — Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following salvage radiotherapy (sRT) informed by prostate-specific membrane antigen (PSMA) PET/CT, a retrospective…